A key decision from Eli Lilly (LLY) — possibly next week — could light up the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record high.
All eyes have been on Lilly's tirzepatide in obesity, but the company is also developing a next-generation approach to weight loss called retatrutide. While tirzepatide hits on two elements that can impact body weight, retatrutide loops in a third.
"We see a reasonable likelihood that Lilly will provide an update on retatrutide, its triple (obesity treatment regimen), on the 2023 guidance call," UBS analyst Colin Bristow said in a note to clients. Lilly has scheduled that call for Tuesday morning.
Representatives of Eli Lilly didn't immediately return a request for comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.